JP2021530229A5 - - Google Patents

Info

Publication number
JP2021530229A5
JP2021530229A5 JP2021502424A JP2021502424A JP2021530229A5 JP 2021530229 A5 JP2021530229 A5 JP 2021530229A5 JP 2021502424 A JP2021502424 A JP 2021502424A JP 2021502424 A JP2021502424 A JP 2021502424A JP 2021530229 A5 JP2021530229 A5 JP 2021530229A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence described
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021502424A
Other languages
English (en)
Japanese (ja)
Other versions
JP7386224B2 (ja
JP2021530229A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041952 external-priority patent/WO2020018503A2/en
Publication of JP2021530229A publication Critical patent/JP2021530229A/ja
Publication of JP2021530229A5 publication Critical patent/JP2021530229A5/ja
Application granted granted Critical
Publication of JP7386224B2 publication Critical patent/JP7386224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021502424A 2018-07-16 2019-07-16 抗il36r抗体 Active JP7386224B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862698482P 2018-07-16 2018-07-16
US62/698,482 2018-07-16
US201962846989P 2019-05-13 2019-05-13
US62/846,989 2019-05-13
US201962866028P 2019-06-25 2019-06-25
US62/866,028 2019-06-25
PCT/US2019/041952 WO2020018503A2 (en) 2018-07-16 2019-07-16 Anti-il36r antibodies

Publications (3)

Publication Number Publication Date
JP2021530229A JP2021530229A (ja) 2021-11-11
JP2021530229A5 true JP2021530229A5 (cg-RX-API-DMAC7.html) 2022-06-13
JP7386224B2 JP7386224B2 (ja) 2023-11-24

Family

ID=67480435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502424A Active JP7386224B2 (ja) 2018-07-16 2019-07-16 抗il36r抗体

Country Status (13)

Country Link
US (3) US11267893B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823989A2 (cg-RX-API-DMAC7.html)
JP (1) JP7386224B2 (cg-RX-API-DMAC7.html)
KR (1) KR102895164B1 (cg-RX-API-DMAC7.html)
CN (1) CN112513091B (cg-RX-API-DMAC7.html)
AU (1) AU2019306217B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020027015A2 (cg-RX-API-DMAC7.html)
CA (1) CA3103531A1 (cg-RX-API-DMAC7.html)
IL (1) IL280013B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021000566A (cg-RX-API-DMAC7.html)
PH (1) PH12020552178A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012360YA (cg-RX-API-DMAC7.html)
WO (1) WO2020018503A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
KR102895164B1 (ko) 2018-07-16 2025-12-04 리제너론 파마슈티칼스 인코포레이티드 항-il36r 항체
MX2023000763A (es) 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
WO2022026832A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
EP4289863A4 (en) * 2020-12-17 2025-04-09 Shanghai Huaota Biopharmaceutical Co., Ltd. BISPECIFIC ANTIBODY AGAINST IL-17A AND IL-36R AND USE THEREOF
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
CN114907477A (zh) * 2021-02-08 2022-08-16 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
CN116963776A (zh) * 2021-03-04 2023-10-27 勃林格殷格翰国际有限公司 治疗gpp的方法
BR112023014103A2 (pt) * 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
WO2022262828A1 (zh) * 2021-06-18 2022-12-22 正大天晴药业集团股份有限公司 抗il-36r抗体及其用途
WO2023285362A1 (en) * 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
WO2023072052A1 (en) * 2021-10-25 2023-05-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗il-36r抗體
CN115724975B (zh) * 2022-10-20 2026-06-09 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
CN116574189A (zh) * 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
WO2024175031A1 (zh) * 2023-02-21 2024-08-29 江苏恒瑞医药股份有限公司 Il-36r结合蛋白及其医药用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6239268B1 (en) 1994-09-09 2001-05-29 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
JPH10508743A (ja) 1994-09-09 1998-09-02 ニューロクライン バイオサイエンシーズ, インコーポレイテッド インターロイキン−1 タイプ3レセプター
JP2004512801A (ja) 1997-10-15 2004-04-30 シェーリング コーポレイション ヒトレセプタータンパク質;関連試薬および方法
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
US20060003323A1 (en) 2000-03-01 2006-01-05 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002050277A2 (en) 2000-12-21 2002-06-27 Curagen Corporation Protein and nucleic acids encoding same
WO2005100604A2 (en) 2004-04-01 2005-10-27 Sequenom, Inc. Methods for identifying risk of osteoarthritis and treatments thereof
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
SI2780373T1 (sl) 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
ES2935257T3 (es) * 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
EP3601350A1 (en) * 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
CA3098040A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
KR102895164B1 (ko) 2018-07-16 2025-12-04 리제너론 파마슈티칼스 인코포레이티드 항-il36r 항체

Similar Documents

Publication Publication Date Title
JP7386224B2 (ja) 抗il36r抗体
TWI432210B (zh) 人類il-23抗原結合蛋白
JP7517999B2 (ja) 抗IL-23p19抗体およびその使用
JP6289520B2 (ja) 中和抗ccl20抗体
US20200010571A1 (en) Bispecific Anti-TNF-Alpha/IL-17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their Use
JP6825033B2 (ja) Baff及びb7rp1に特異的なタンパク質及びその使用
JP5818804B2 (ja) ヒトil−22raに対するヒト化抗体
JP6410712B2 (ja) Il−6結合分子
KR20110040886A (ko) 프로스타글란딘 e2 결합 단백질 및 이의 용도
KR20110110349A (ko) Il-1 결합 단백질
JP2017533705A (ja) 抗tnf−/抗il−23二重特異性抗体
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
TW201917135A (zh) 抗TNF/抗IL-23 IgG雙特異性抗體
JP2023537422A (ja) Il-11の抗体及びその使用
WO2019148405A1 (zh) IL-4Rα抗体及其用途
CN113166239B (zh) 抗il-17a抗体及其应用
WO2016070769A1 (zh) 同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
TW202144425A (zh) 特異性抗原結合分子,其製備方法及醫藥用途
EP4357361A1 (en) Anti-il-36r antibody and use thereof
US12134644B2 (en) Anti-IL-17A antibodies and use thereof
HK40123789A (en) Optimized anti-tl1a antibodies
HK40042163B (en) Optimized anti-tl1a antibodies
EA049652B1 (ru) Антитела к il36r